Summit Global Investments’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-19,259
Closed -$1.73M 596
2024
Q4
$1.73M Buy
+19,259
New +$1.87M 0.11% 144

Other funds holding XBI

Summit Global Investments's XBI Position: Q1 2025 in Review

Summit Global Investments sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2025, closing a stake of 19,259 shares — an estimated $1.73M sold.

Summit Global Investments first reported a position in XBI in Q4 2024 and held it in 1 quarter. The position peaked at $1.73M in Q4 2024. 682 funds tracked by Wall St. Rank hold XBI as of Q1 2025.

  • Summit Global Investments reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2025 after selling out during the quarter.
  • Summit Global Investments sold 19,259 State Street SPDR S&P Biotech ETF shares in Q1 2025, an estimated $1.73M.
  • Summit Global Investments first reported a position in State Street SPDR S&P Biotech ETF in Q4 2024 and held it in 1 quarter.
  • Summit Global Investments's State Street SPDR S&P Biotech ETF position peaked at $1.73M in Q4 2024.
  • 682 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2025.

Based on Summit Global Investments's 13F filing for Q1 2025, filed 7 Apr 2025.